Navigation Links
Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
Date:3/20/2008

Biologically active tissue adhesive allows for placement of skin grafts

without staples or sutures

DEERFIELD, Ill., March 20 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation announced today the U.S. Food and Drug Administration (FDA) approval of ARTISS (Fibrin Sealant (Human)), the first and only slow-setting fibrin sealant indicated for use in adhering skin grafts in adult and pediatric burn patients. ARTISS was developed using Baxter's proven fibrin sealant technology platform and is the newest agent in the company's expanding BioSurgery portfolio.

ARTISS allows for the delayed setting and controlled manipulation of skin grafts for approximately 60 seconds, relative to rapid-setting fibrin sealants, which set in five to 10 seconds. Skin grafts can be fixed without the use of staples or sutures, which may help reduce post-operative complications and patient anxiety about pain during staple removal. Baxter will launch ARTISS at the American Burn Association (ABA) 40th Annual Meeting held April 29 -- May 2, 2008 in Chicago.

"ARTISS is a safe and effective alternative to staples, reducing discomfort among burn patients requiring skin grafts," said Ron Lloyd, general manager, BioSurgery. "This is another example of Baxter's scientific leadership in specialty biologic products, serving needs of patients and physicians."

The FDA approval is based on Phase III study results, which were also published in the March/April 2008 issue of The Journal of Burn Care and Research. The multi-center, prospective, randomized, controlled and blinded study compared the use of ARTISS to staples in 138 burn patients requiring skin grafting. ARTISS is safe and effective for attaching skin grafts with outcomes as good as staple fixation.

Frequent adverse events, seen in both treatment groups, included bleeding and fluid collection in the tissues, both of which are common during skin grafting procedures.

ARTISS
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
2. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
3. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
4. Baxter Declares Quarterly Dividend
5. Baxter Provides Update on Heparin Reactions
6. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
7. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
8. Baxter International Fourth Quarter 2007 Financial Results Conference Call
9. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
10. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
11. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... to manufacture proteins including biosimilar therapeutics, today provided ... the second quarter ended June 30, 2014. ... public offering, we have the capital to continue ... our proprietary protein expression platform," stated Bertrand C. ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... product to poultry, red meat and pork processing ... ... 19 Tasker Products Corp.,(OTC Bulletin Board: TKER), a distributor and ... has received authorization from the Food Safety and Inspection,Service ("FSIS") of ...
... Biotechnologies,announced today the results of an on-going Phase I/II ... ASCO meeting, 2008).,Continuing on with the planned dose-escalations of ... in a Phase I safety study (Molecular,Therapy, 2008), the ... i.v. two to three times a week for 4,weeks, ...
... Lack of Global Statistics Prompts Creation of First Global,Resource ... Alliance, a newly formed Non-Governmental,Organisation, today called on governments ... prevention, diagnosis and treatment for people living,with chronic viral ... that 500 million, approximately one in 12,people, are infected ...
Cached Biology Technology:Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 2Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 3ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer 2World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic 2World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic 3
(Date:8/31/2014)... new study of satellite data from the last 19 years ... sea-level around the coast of Antarctica to rise by 2cm ... the University of Southampton detected the rapid rise in sea-level ... than a million square kilometres. , The melting ... ice shelves has contributed an excess of around 350 gigatonnes ...
(Date:8/31/2014)... CAMBRIDGE, MA -- Over the past several decades, malaria diagnosis ... a patient, a technician smears the blood across a glass ... a microscope for the Plasmodium parasite, which causes the disease. ... are in the blood an important measure of disease ... for human error. , A research team from the Singapore-MIT ...
(Date:8/29/2014)... UC Davis have made some surprising discoveries about ... simian immunodeficiency virus (SIV), the team found that ... are early responders to viral invasion and are ... cytokine called interleukin-1 beta (IL-1β). , Though ... breakdown of the gut epithelium that provides a ...
Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3The early cost of HIV 2
... eastern Pacific populations of leatherback turtles, the 21st century ... change could exacerbate existing threats and nearly wipe out ... nests buried at hotter, drier beaches are the leading ... a new study in the journal Nature Climate ...
... 2012 Scientists at The Scripps Research Institute have discovered ... within cells. The scientists highlighted the medical potential of the ... to an experimental gene therapy against HIV infection. "We ... the troubles that have long been linked to traditional gene ...
... highly valued, highly cited research and reviews to the ... report that the new impact factors align with community ... the highest impact research and reviews in the biomedical ... by Thomas Reuters. Cell Press,s flagship journal ...
Cached Biology News:Rising heat at the beach threatens largest sea turtles, climate change models show 2Rising heat at the beach threatens largest sea turtles, climate change models show 3Scripps Research Institute Scientists Develop Alternative to Gene Therapy 2Scripps Research Institute Scientists Develop Alternative to Gene Therapy 3Scripps Research Institute Scientists Develop Alternative to Gene Therapy 4Cell Press journals continue to deliver high impact 2Cell Press journals continue to deliver high impact 3
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Mycoplasma and virus tested...
... MagicMark XP Western Protein Standards are ... protein molecular weight estimation directly on ... an IgG binding site, allowing direct ... used to detect your target protein ...
... Clone/PAD: 3F10B10. Immunogen: Synthetic ... region of JAB1 (Jun activation ... Specificity: Specific for the JAB1 ... controls: 293T Jurkat cell lysates). ...
Biology Products: